Navigation Links
Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Date:1/14/2008

America and Europe.

The company's second Phase 3 trial, VITAL-2, is a multi-center, randomized, controlled Phase 3 clinical trial designed to evaluate the safety and efficacy of GVAX immunotherapy for prostate cancer used in combination with Taxotere chemotherapy compared to the use of Taxotere chemotherapy and prednisone in HRPC patients with metastatic disease who are symptomatic with cancer-related pain. The primary endpoint of the trial is also an improvement in survival. VITAL-2 was initiated in June 2005 and is currently enrolling patients at approximately 90 sites in North America and Europe. The company expects to complete enrollment of approximately 600 patients in the first half of 2009 and if this is achieved, to have a sufficient number of events for a pre-planned interim analysis at that time.

The U.S. Food and Drug Administration (FDA) granted Cell Genesys Special Protocol Assessments (SPAs) for both VITAL-1 and VITAL-2. The SPA is a process that allows for official FDA evaluation of a Phase 3 clinical trial and provides trial sponsors with a binding written agreement that the design and analysis of the study are adequate to support a license application submission if that study is performed according to the SPA. Cell Genesys completed the modifications requested by FDA during the review process.

About GVAX Cancer Immunotherapies

GVAX cancer immunotherapies are non patient-specific investigational therapeutics comprised of whole tumor cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony stimulating factor), an immune stimulatory hormone, and then irradiated for safety. GVAX is designed to be administered through intradermal injections on an outpatient basis. To date, over 600 patients have been treated with GVAX cancer immunotherapies in Phase 1 and Phase 2 clinical trials for multiple indications, including prostate cancer, pancreatic cancer, and leukemia. The company is currently manufacturing GV
'/>"/>

SOURCE Cell Genesys, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
11. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... SAN FRANCISCO , May 5, 2015 ... a Small Business Innovation Research (SBIR) grant from the ... Creek is a San Francisco ... therapeutics to selectively repair tissues damaged by disease. This ... therapeutics engineered to repair heart tissue following a heart ...
(Date:5/5/2015)... , May 5, 2015 Ardelyx, Inc. ... focused on cardio-renal, gastrointestinal, and metabolic diseases, today ... evaluating tenapanor in Stage 3 chronic kidney disease ... did not meet the primary endpoint of decreasing ... to patients receiving placebo. Ardelyx ...
(Date:5/5/2015)... , May 5, 2015 North ... $94.9 million in 2014, and is estimated to grow ... 7.8% from 2014 to 2019. Browse through ... Market for an analysis of industry trends and segments, ... http://www.micromarketmonitor.com/market/north-america-glaucoma-surgery-devices-8830146604.html Early buyers ...
Breaking Medicine Technology:Silver Creek Pharmaceuticals Awarded NIH SBIR Grant for Smart Growth Factor Technology 2Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 2Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 4Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 5Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 6North America Ophthalmology Glaucoma Surgery Device Market is Expected to Reach $138.3 Million by 2019, at a CAGR of 7.8% From 2014 to 2019 2North America Ophthalmology Glaucoma Surgery Device Market is Expected to Reach $138.3 Million by 2019, at a CAGR of 7.8% From 2014 to 2019 3
... Further,Scientific Validation of the Potential Utility of Modigene,s CTP Technology ... ... -, VIENNA, Va., Sept. 24 Modigene Inc. (OTC,Bulletin Board: ... edition of the journal Endocrinology showing that,erythropoietin (EPO) linked to Modigene,s ...
... FRAMINGHAM, Mass., Sept. 24 Iodine has been ... has been written about molecular,iodine yet many women ... studies being conducted may soon yield an effective,nonhormonal ... drugs on the market, all,available hormonal therapies have ...
Cached Medicine Technology:Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs 2Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs 3Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs 4Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease 2
(Date:5/5/2015)... 05, 2015 Carlini CPA, PLLC is ... Matthews, Charlotte and surrounding areas. The company has over ... This company provides assistance in making informed decisions about ... individual or corporate tax returns for their clients. ... that allows clients (and Carlini CPA) to pass documents ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Horizon Blue ... its strong and secure credit rating of “A” from ... BCBSNJ’s financials last week, the Wall Street ratings agency ... “leading market position” in determining the rating and “stable” ... is one of our top priorities, so we are ...
(Date:5/5/2015)... The 2015 Crystal Ball, hosted by the Hepatitis ... outreach and patient advocacy programs. The gala evening included dancing, ... hundreds of supporters. , The 2015 gala was dedicated to ... virus (HBV) by Dr. Baruch S. Blumberg, who passed away ... for his discovery of the virus in 1976. He and ...
(Date:5/5/2015)... New York, NY (PRWEB) May 05, 2015 The ... based on the experiences of Dr. Brad Reedy from ... When Judith Regan was asked why she chose to publish a ... me as a parent (and publisher) is the idea that it ... question...that we and our children are on the trek sometimes together ...
(Date:5/5/2015)... Los Angeles, CA (PRWEB) May 05, 2015 ... to treat and actually prevent a variety of health ... Doc utilized this modern research to adopt clean eating ... preservatives and artificial dyes associated with over-consumption of fast ... eating diet plans easy to follow and report ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Maintains “A” Credit Rating from Standard & Poor’s 2Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 2Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 3Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 2Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 3Health News:Diet Doc Introduces Diet Plans that Teach Patients how to Eat Clean by Getting Back to Basics and Exchanging Processed Foods for Clean, Nutritious Foods 2Health News:Diet Doc Introduces Diet Plans that Teach Patients how to Eat Clean by Getting Back to Basics and Exchanging Processed Foods for Clean, Nutritious Foods 3
... Equip for Equality Obtains Federal Injunction Against the State ... 30 Following two years of,federal court litigation under ... permanent injunction to enable its client, David,Grooms, to receive ... order,overturned a decision by the Illinois Department of Healthcare ...
... as fact , , MONDAY, June 30 (HealthDay News) -- A new ... and loss of memory. , The study, which has followed thousands ... loss of memory on a word test for those at age ... highest levels. By age 60, the rate of memory loss had ...
... 20 percent of people worldwide suffer from migraines ... By studying a rare, inherited form of migraine, researchers ... the biological basis of the painful, debilitating disorder. , ... Sciences, Alfred George Jr., M.D., and colleagues report ...
... Backyard barbecues and beach bonfires are beloved summer activities ... especially children at risk of painful, long-term injury. ... Center director, urges extra caution with the use and ... at campsites. "We,re seeing approximately two dozen firepit injuries ...
... June 30 As heat waves plague much of,the United ... director,for the famed nonprofit Los Angeles Jewish Home -- one ... Angeles -- has,offered tips for the nation,s elderly to avoid ... United States, about 200 people die of health problems,caused by ...
... to be included as part of company,s, comprehensive Pressure Ulcer ... ... pressure ulcers, MUNDELEIN, Ill., June 30 Medline Industries, ... room table pads and stretcher pads aimed at helping,hospitals and ...
Cached Medicine News:Health News:Young Man With Severe Disabilities Wins Right to Services From State Enabling Him to Live At Home 2Health News:Young Man With Severe Disabilities Wins Right to Services From State Enabling Him to Live At Home 3Health News:Research Links Low HDL Levels With Memory Loss 2Health News:Migraine mutations reveal clues to biological basis of disorder 2Health News:From beach to backyard, caution can reduce firepit burns 2Health News:Medical Director for Renowned Los Angeles Jewish Home Offers Top Tips to Elderly in Coping With Searing Temperatures Across U.S. 2Health News:Medical Director for Renowned Los Angeles Jewish Home Offers Top Tips to Elderly in Coping With Searing Temperatures Across U.S. 3Health News:Medline Announces Advanced Line of Therapeutic Mattresses, Operating Room Table Pads and Stretcher Pads 2Health News:Medline Announces Advanced Line of Therapeutic Mattresses, Operating Room Table Pads and Stretcher Pads 3
Langenbeck periosteal elevators, wide, blade width 11/16" (17 mm), length 7 1/2" (191 mm)....
Cushing periosteal elevators, Gutsch handle, sharp, narrow, blade width 3/16" (5 mm), length 7 5/8" (194 mm)....
Lederer periosteal elevators....
Miller Collburn periosteal elevators....
Medicine Products: